Stated plainly: 2.4 mg · cagrilintide.
I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.
My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.
Why does this happen, and what would falsify the usual explanation?
Two administrations of 1.2 mg instead of one of 2.4 mg — the same 2.4 mg a week either way. Total weekly exposure is unchanged; what changes is the peak-to-trough ratio, and for an agent with a half-life measured in days the trough barely moves because the dosing interval is already short relative to it. The arithmetic is the easy part: 2.4 ÷ 2 = 1.2. Whether it is worth doing is a pharmacokinetic question, and nothing here is medical advice.
To be exact about it, this is one of the questions where the pharmacokinetics gives a clean answer and the anecdotal reports disagree with it.
Splitting that same weekly dose into two half-doses at 3.5-day intervals gives τ/t½ = 0.5 and a peak-to-trough ratio of about 1.41. The profile is flatter, and the difference between a 2-fold and a 1.4-fold swing is not obviously perceptible.
| Configuration | Dead volume | Loss at 5 mg/mL | Over 20 draws |
|---|---|---|---|
| Fixed-needle insulin syringe | 3–5 µL | 15–25 µg | 0.3–0.5 mg |
| Low-dead-space, detachable | <2 µL | <10 µg | <0.2 mg |
| Standard luer-lock + 30G | 35–60 µL | 175–300 µg | 3.5–6 mg |
| Luer-lock + 21G drawing needle | 70–100 µL | 350–500 µg | 7–10 mg |
Specifically, a slower titration achieves a lower peak exposure with fewer handling steps, which is why it is the better-evidenced answer to the same problem.
Published half-lives for the agents in this class range from about thirteen hours to about a week, which is the range over which the answer changes.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Slower titration has evidence; splitting has anecdote. Prefer the first.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemIf the goal is tolerability, a slower titration has better evidence behind it than a split schedule.
Accumulation to steady state takes four to five half-lives regardless of how the dose is divided. Splitting does not shorten it and does not change the average exposure.
The part that matters: for a thirteen-hour half-life agent dosed daily, τ/t½ is about 1.8 and the swing is nearly fourfold, which is why the daily agents feel peakier and why splitting them would have more effect.
Titration schedules in the trial programmes were designed to manage gastrointestinal tolerability and are the evidenced approach to that problem.
The caveat is that no split schedule has been evaluated in a trial, so the whole discussion is inference plus report.
Every split is another stopper entry. Count that cost.
edited 20 Aug 2025 by tenth_of_a_unit — clarified the distinction between purity and content
Answering this needs the specific agent, because the answer for a thirteen-hour half-life and a one-week half-life are opposite.
Each additional injection is an additional stopper entry, an additional needle and an additional opportunity to introduce contamination into a preparation that has no release testing behind it.
It helps to be literal here: for a drug with elimination half-life t½ dosed at interval τ, the peak-to-trough ratio at steady state is 2^(τ/t½). With a one-week half-life dosed weekly, τ/t½ = 1, so the ratio is 2 — a factor of two between peak and trough, which is already flat by pharmacological standards.
No trial in this class has evaluated a split schedule against the licensed one, so any comparison is anecdotal.
If you cannot read half the dose accurately, you cannot split it accurately.
Answer first: splitting a weekly dose into smaller more frequent doses reduces peak-to-trough variation, and whether that helps depends entirely on the half-life of the agent.
Halving a dose accurately requires the reading resolution to support it. A 10-unit dose split into two 5-unit doses is at the coarse end of any barrel.
The peak-to-trough relationship 2^(τ/t½) is standard pharmacokinetics for a one-compartment model with first-order elimination and is the correct tool for this question.
Work out 2^(τ/t½) for your agent before arguing about this. It usually settles it.
Start with the half-life. For an agent with a one-week half-life, weekly dosing already produces a nearly flat profile and splitting changes very little.
Reported tolerability improvements with splitting may reflect the smaller absolute amount arriving at once rather than the exposure profile, which is a different mechanism and is not well characterised.
The general principle here — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science, and it is why licensed presentations contain a surfactant such as polysorbate 20 or 80. A research vial does not, which is precisely why handling matters more, not less.
Halving a dose you cannot read accurately introduces an error larger than the effect you are chasing.
For a weekly half-life, weekly dosing is already flat. Splitting buys very little.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.